Approval of Novel TB Drug Celebrated—With Restraint
Abstract
On New Year's Eve, the U.S. Food and Drug Administration approved the first new tuberculosis drug in more than 40 years.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bedaquiline was the first new drug approved for TB in more than 40 years.
“bedaquiline was the first new drug approved in more than 40 years (ref. 121 )”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [121]
Cited by
Sorted by citations
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439 · see citing works
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A. I., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 895 · see citing works
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520 · see citing works
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Andries, K., Villellas, C., Coeck, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102135 · Cited by 440 · see citing works
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 381 · see citing works
“From these new rug candidates, the semi-synthetic TMC207 has received FDA pproval, specifically for patients with MDR-TB, through its accelerted approval programme which based its decision on Phase II trials Cohen, 2013; Diacon et al., 2009, 2012).”
BackgroundInfluentialProspects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 373 · see citing works
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 329 · see citing works
“Bedaquiline has been associated with QT-prolongation and must be carefully combined with other drugs that share this risk, including fluoroquinolones, macrolides, clofazimine, or drugs that inhibit CYP3A4, which may increase its exposure [15].”
BackgroundKoul, A., Vranckx, L., Dhar, N., Göhlmann, H. W. H., Özdemir, E., Neefs, J., Schulz, M., Lü, P., Mørtz, E., McKinney, J. D., et al. (2014) · Nature Communications · doi:10.1038/ncomms4369 · Cited by 289 · see citing works
21st Century Natural Product Research and Drug Development and Traditional Medicines
Ngo, L., Okogun, J., & Folk, W. (2013) · Natural product reports (Print) · doi:10.1039/c3np20120a · Cited by 229 · see citing works
Bactericidal mode of action of bedaquiline
Hards, K., Robson, J. R., Berney, M., Shaw, L. E., Bald, D., Koul, A., Andries, K., & Cook, G. M. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv054 · Cited by 228 · see citing works
Almeida, D. V., Ioerger, T. R., Tyagi, S. K., Li, S., Mdluli, K. E., Andries, K., Grosset, J. H. E., Sacchettini, J. C., & Nuermberger, E. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00753-16 · Cited by 210 · see citing works
“Food and Drug Administration as part of combination therapy for MDR-TB when other alternatives are not available (2).”
BackgroundLi, X., Hernandez, V. S., Rock, F. L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00631 · Cited by 167 · see citing works
Shirude, P. S., Shandil, R. K., Sadler, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401382v · Cited by 164 · see citing works
Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis
Rao, S. P. S., Lakshminarayana, S. B., Kondreddi, R. R., Herve, M., Camacho, L. R., Bifani, P. J., Kalapala, S. K., Jiřiček, J., Ma, N. L., Tan, B. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007355 · Cited by 148 · see citing works
“ScienceT tion for the treatment of MDR TB patients as a part of combination therapy (9).”
BackgroundThe DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
Riccardi, G., Pasca, M. R., Chiarelli, L. R., Manina, G., Mattevi, A., & Binda, C. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5218-x · Cited by 130 · see citing works
A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
Fox, G. J., & Menzies, D. (2013) · Infectious Diseases and Therapy · doi:10.1007/s40121-013-0009-3 · Cited by 122 · see citing works
Lü, P., Heineke, M. H., Koul, A., Andries, K., Cook, G. M., Lill, H., van Spanning, R. J. M., & Bald, D. (2015) · Scientific Reports · doi:10.1038/srep10333 · Cited by 119 · see citing works
ATP synthase in mycobacteria: Special features and implications for a function as drug target
Lü, P., Lill, H., & Bald, D. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.01.022 · Cited by 114 · see citing works
Chahine, E. B., Karaoui, L. R., & Mansour, H. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504087 · Cited by 114 · see citing works
“This may shorten the duration of treatment, improve adherence, achieve higher cure rates, and preserve the activity of the background regimen.(41) However, concerns regarding increased mortality restrict bedaquiline use to cases where no alternative options are possible.”
BackgroundTuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm : Figure 1.Preprint
Chakraborty, S., & Rhee, K. Y. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021147 · Cited by 113 · see citing works
“1(5)) is also the first FDA-approved drug to have been developed in the modern era of molecular sciences (Cohen 2013).”
BackgroundAntimicrobial peptides as novel anti-tuberculosis therapeutics
Silva, J. P., Appelberg, R., & Gama, M. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.05.007 · Cited by 107 · see citing works
Current perspectives in drug discovery against tuberculosis from natural products
Nguta, J. M., Appiah‐Opong, R., Nyarko, A. K., Yeboah‐Manu, D., & Addo, P. (2015) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2015.05.004 · Cited by 106 · see citing works
Kondreddi, R. R., Jiřiček, J., Rao, S. P. S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012774 · Cited by 103 · see citing works
Tang, J., Wang, B., Wu, T. S., Wan, J., Tu, Z., Njire, M. M., Wan, B., Franzblauc, S. G., Zhang, T., Lu, X., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00176 · Cited by 96 · see citing works
Alexander, D. C., Vasireddy, R., Vasireddy, S., Philley, J. V., Brown‐Elliott, B. A., Perry, B. J., Griffith, D. E., Benwill, J. L., Cameron, A. D. S., & Wallace, R. J. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02087-16 · Cited by 91 · see citing works
“Food and Drug Administration (FDA) for MDR tuberculosis (TB) treatment in combination with other active tuberculosis drugs (5).”
BackgroundNovel drugs against tuberculosis: a clinician's perspective
Olaru, I. D., von Groote-Bidlingmaier, F., Heyckendorf, J., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00162314 · Cited by 89 · see citing works
Advanced drug delivery and therapeutic strategies for tuberculosis treatment
Nair, A., Greeny, A., Nandan, A., Sah, R. K., Jose, A., Dyawanapelly, S., Junnuthula, V., Athira, K. V., & Sadanandan, P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02156-y · Cited by 99 · see citing works
Lu, X., Williams, Z. C., Hards, K., Tang, J., Cheung, C., Aung, H. L., Wang, B., Liu, Z., Hu, X., Lenaerts, A. J. M., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00225 · Cited by 84 · see citing works
Metabolic and Bactericidal Effects of Targeted Suppression of NadD and NadE Enzymes in Mycobacteria
Rodionova, I. A., Schuster, B. M., Guinn, K. M., Sorci, L., Scott, D. A., Li, X., Kheterpal, I., Shoen, C. M., Cynamon, M. H., Locher, C. P., et al. (2014) · mBio · doi:10.1128/mbio.00747-13 · Cited by 82 · see citing works
Tomatidine Is a Lead Antibiotic Molecule That Targets Staphylococcus aureus ATP Synthase Subunit C
Boulet, M. L., Isabelle, C., Guay, I., Brouillette, É., Langlois, J.-P., Jacques, P., Rodrigue, S., Brzeziński, R., Beauregard, P. B., Bouarab, K., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02197-17 · Cited by 79 · see citing works
“Bedaquiline, now approved for the treatment of Mycobacterium tuberculosis infections (39), is an ATP synthase subunit C inhibitor specific to Mycobacterium (10).”
BackgroundStructure–activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis
Meissner, A., Boshoff, H. I., Vasan, M., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.048 · Cited by 78 · see citing works
The role of delamanid in the treatment of drug-resistant tuberculosis
Sloan, D. J., & Lewis, J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s71076 · Cited by 77 · see citing works
“the diarylquinoline ATP-synthase inhibitor, bedaquiline, was the first new anti-TB agent to be licensed since rifampicin in 1967.(15) Two members of the dihydro-nitroimidazole class (delamanid [formerly OPC-67863] and pretomanid [formerly PA-824]) are also undergoing advanced clinical assessment.”
The role of moxifloxacin in tuberculosis therapy
Gillespie, S. H. (2016) · European Respiratory Review · doi:10.1183/16000617.0085-2015 · Cited by 76 · see citing works
Tenero, D. M., Derimanov, G. S., Carlton, A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00240-19 · Cited by 75 · see citing works
Moodley, S., Koorbanally, N. A., Moodley, T., et al. (2014) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2014.06.014 · Cited by 64 · see citing works
Sharma, A. B., Dutta, P., Sharma, M., et al. (2014) · Journal of Cheminformatics · doi:10.1186/s13321-014-0046-2 · Cited by 64 · see citing works
Targeting the ATP synthase in bacterial and fungal pathogens: beyond Mycobacterium tuberculosis
Vestergaard, M. R., Bald, D., & Ingmer, H. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.01.026 · Cited by 60 · see citing works
Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents
Lv, K., You, X., Wang, B., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00106 · Cited by 61 · see citing works
Wang, Z., Soni, V., Marriner, G. A., Kaneko, T., Boshoff, H. I., Barry, C. E., & Rhee, K. Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907946116 · Cited by 62 · see citing works
“On this basis, BDQ was approved by the US Food and Drug Administration for the treatment of pulmonary multidrug-resistant TB as part of combination therapy in adults (13).”
MethodSAR analysis of new anti-TB drugs currently in pre-clinical and clinical development
Poce, G., Cocozza, M., Consalvi, S., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.066 · Cited by 59 · see citing works
Recent advances in the development of vaccines for tuberculosis
Ahsan, M. J. (2015) · Therapeutic Advances in Vaccines · doi:10.1177/2051013615593891 · Cited by 57 · see citing works
“However, both dugs induce arrhythmia, and are recommended only in patients for whom other treatment has failed [Cohen, 2013; Ryan and Lo, 2014] (http://www.ema.europa.eu).”
BackgroundXu, J., Converse, P. J., Upton, A. M., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02418-20 · Cited by 57 · see citing works
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents
Ng, P. S., Manjunatha, U. H., Rao, S. P. S., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.008 · Cited by 56 · see citing works
Zhou, F.-W., Lei, H. J., Li, F., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.010 · Cited by 53 · see citing works
Almeida, D., Converse, P. J., Li, S.-Y., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01412-21 · Cited by 49 · see citing works
“(FDA) for treatment of tuberculosis (TB) in four decades (1).”
BackgroundMills, H. L., Cohen, T., & Colijn, C. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005260 · Cited by 49 · see citing works
“As new TB drugs are introduced to themarket (40), the opportunity to use these drugs as monotherapy among contacts of individuals with highly drug-resistant disease has been suggested (41).”
Xu, J., Tasneen, R., Peloquin, C. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01692-17 · Cited by 49 · see citing works
New Drugs and Treatment Regimens
Sloan, D. J., Davies, G., & Khoo, S. (2013) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x113099990017 · Cited by 48 · see citing works
“In view of the urgent need for new drugs, the US Food and Drug Administration granted accelerated approval and licensing of bedaquiline for use in MDR-TB regimens in 2012 [63].”
BackgroundGao, C., Peng, C., Shi, Y., You, X., Ran, K., Xiong, L., Ye, T.-H., Zhang, L., Wang, N., Zhu, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep29717 · Cited by 48 · see citing works
New drugs for the treatment of Mycobacterium tuberculosis infection
AlMatar, M., AlMandeal, H., Var, İ., Kayar, B., & Köksal, F. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.105 · Cited by 49 · see citing works
Igarashi, M., Ishizaki, Y., & Takahashi, Y. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.126 · Cited by 46 · see citing works
Hards, K., Cheung, C., Waller, N. J. E., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03110-8 · Cited by 46 · see citing works
de Melo, C. S., Feng, T., van der Westhuyzen, R., Gessner, R. K., Street, L. J., Morgans, G. L., Warner, D. F., Moosa, A., Naran, K., Lawrence, N., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.10.021 · Cited by 47 · see citing works
Current advances in the clinical development of anti-tubercular agents
Tetali, S. R., Kunapaeddi, E., Mailavaram, R. P., Singh, V., Borah, P., Deb, P. K., Venugopala, K. N., Hourani, W., & Tekade, R. K. (2020) · Tuberculosis · doi:10.1016/j.tube.2020.101989 · Cited by 45 · see citing works
Albesa-Jové, D., Chiarelli, L. R., Makarov, V., Pasca, M. R., Urresti, S., Mori, G., Salina, E. G., Vocat, A., Comino, N., Mohorko, E., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500149m · Cited by 44 · see citing works
Lu, X., Tang, J., Cui, S., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.030 · Cited by 44 · see citing works
Wu, Z., Lu, Y., Li, L., Zhao, R., Wang, B., Lv, K., Liu, M., & You, X. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00330 · Cited by 45 · see citing works
Rehberg, N., Akoné, S. H., Ioerger, T. R., Erlenkamp, G., Δαλέτος, Γ., Gohlke, H., Proksch, P., & Kalscheuer, R. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00055 · Cited by 45 · see citing works
TARGETING DORMANT BACILLI TO FIGHT TUBERCULOSIS
Fattorini, L., Piccaro, G., Mustazzolu, A., & Giannoni, F. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.072 · Cited by 43 · see citing works
Zhang, R., Lv, K., Wang, B., et al. (2017) · RSC Advances · doi:10.1039/c6ra25712g · Cited by 43 · see citing works
Zhang, D., Liu, Y., Zhang, C., et al. (2014) · Molecules · doi:10.3390/molecules19044380 · Cited by 42 · see citing works
“Despite the progress, there is still an urgent need for new and more effective therapy for the treatment MDR-TB and repurposing or optimizing existing antibiotics has been proved an effective approach in identifying new TB drugs [2,4].”
BackgroundCholesterol metabolism: a potential therapeutic target in Mycobacteria
Abuhammad, A. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13694 · Cited by 42 · see citing works
“These efforts culminated in the approval of two new drugs for the treatment of MDR-TB as part of a combination regimen: the ATP synthase inhibitor bedaquiline (Andries et al., 2005; Cohen, 2013; Pym et al., 2015) and delamanid (Blair and Scott, 2015; Gupta et al., 2015; WHO, 2015).”
BackgroundDesign, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety
Lv, K., Tao, Z., Liu, Q., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.060 · Cited by 41 · see citing works
Evans, J. C., & Mizrahi, V. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00812 · Cited by 39 · see citing works
“…led to the recent development of bedaquiline (Sirturo; Andries et al., 2005), the first FDA-approved drug for the treatment of TB in over 40 years (Cohen, 2013); delamanid (Deltyba), which received conditional approval by the European Medicines Agency in 2013 and is being evaluated in a phase 3…”
BackgroundThe contrasting cultures of HIV and tuberculosis care
Daftary, A., Calzavara, L., & Padayatchi, N. (2014) · AIDS · doi:10.1097/qad.0000000000000515 · Cited by 39 · see citing works
Laborde, J., Deraeve, C., & Bernardes‐Génisson, V. (2017) · ChemMedChem · doi:10.1002/cmdc.201700424 · Cited by 39 · see citing works
Shah, N. B., & Duncan, T. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.665059 · Cited by 36 · see citing works
“Mycobacterial ATP synthase is the target of a new class of antibiotics, the diarylquinolines, and the lead drug, bedaquiline, has been approved for treatment of multidrug-resistant tuberculosis (25, 69).”
BackgroundTanner, L., Denti, P., Wiesner, L., & Warner, D. F. (2018) · IUBMB Life · doi:10.1002/iub.1866 · Cited by 35 · see citing works
Update in Tuberculosis and Nontuberculous Mycobacterial Disease 2012
Menzies, D., & Nahid, P. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0687up · Cited by 32 · see citing works
Kim, T., Hanh, B. T. B., Heo, B. E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115936 · Cited by 30 · see citing works
“It is a diarylquinoline antibiotic that targets the essential FoF1 ATP synthase [25,26].”
BackgroundTantry, S. J., Shinde, V. N., Balakrishnan, G., et al. (2016) · MedChemComm · doi:10.1039/c5md00589b · Cited by 28 · see citing works
Identification and synthesis of novel inhibitors of mycobacterium ATP synthase
Surase, Y. B., Samby, K., Amale, S. R., Sood, R., Purnapatre, K. P., Pareek, P. K., Das, B., Nanda, K., Kumar, S., & Verma, A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.081 · Cited by 28 · see citing works
Rani, A., Johansen, M. D., Roquet, F., Kremer, L., Awolade, P., Ebenezer, O., Singh, P., Sumanjit, & Kumar, V. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127576 · Cited by 26 · see citing works
Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents
Sharma, K., Tanwar, O., Deora, G. S., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.053 · Cited by 24 · see citing works
Targeting mycobacterial membranes and membrane proteins: Progress and limitations
Kumar, G., & Kapoor, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117212 · Cited by 26 · see citing works
Liu, J., Ren, Z., Fan, L., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.035 · Cited by 24 · see citing works
Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Woods, G. L., Lin, S.-Y. G., & Desmond, E. P. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch76 · Cited by 24 · see citing works
Synthesis of new 7-chloro-4-phenoxyquinoline analogues as potential antitubercular agents
Salve, P. S., & Alegaon, S. G. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-1970-2 · Cited by 22 · see citing works
“Further, bedaquiline, a quinoline derivative was launched as an antitubercular agent recently (Chan et al. 2013; Cohen 2013).”
BackgroundA review of recent advances in anti-tubercular drug development
Umumararungu, T., Mukazayire, M.-J., Mpenda, M., et al. (2020) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2020.07.017 · Cited by 20 · see citing works
Shalini, S., Viljoen, A. J., Kremer, L., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.03.021 · Cited by 20 · see citing works
The Redox State Regulates the Conformation of Rv2466c to Activate the Antitubercular Prodrug TP053
Albesa-Jové, D., Comino, N., Tersa, M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677039 · Cited by 19 · see citing works
Dihydroartemisinin and its Analogs: A New Class of Antitubercular Agents
Kalani, K., Chaturvedi, V., Trivedi, P., et al. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304142802 · Cited by 19 · see citing works
Filling the Pipeline - New Drugs for an Old Disease
Stehr, M., Elamin, A. A., & Singh, M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026613666131113152908 · Cited by 18 · see citing works
Wang, A., Ma, C., Chai, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112409 · Cited by 18 · see citing works
Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)
Field, S. K. (2013) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s11675 · Cited by 18 · see citing works
Response of Mycobacterium smegmatis to the Cytochrome bcc Inhibitor Q203
Chauhan, P., van der Meulen, S. A., Caetano, J. M. S., Goojani, H. G., Botman, D., van Spanning, R. J. M., Lill, H., & Bald, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810331 · Cited by 16 · see citing works
Xu, J., Li, D., Shi, J., Wang, B., Ge, F., Guo, Z., Mu, X., Nuermberger, E. L., & Lu, Y. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01532-22 · Cited by 16 · see citing works
“drug in over 4 decades (2), and it is now classified as a group A drug (to be included in”
BackgroundSingh, A., Viljoen, A. J., Kremer, L., et al. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0098 · Cited by 17 · see citing works
Prevention and treatment of tuberculosis in solid organ transplant recipients
Abad, C. L. R., & Razonable, R. R. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1704255 · Cited by 17 · see citing works
“Bedaquiline has a black-box warning due to its potential to induce arrhythmia [101].”
BackgroundScaini, J. L., Camargo, A., Seus, V., et al. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.11.016 · Cited by 16 · see citing works
Li, L., Li, Z., Liu, M., Shen, W., Wang, B., Guo, H., & Lu, Y. (2015) · Molecules · doi:10.3390/molecules21010049 · Cited by 16 · see citing works
Hybridization Approach to Drug Discovery Inhibiting Mycobacterium tuberculosis-An Overview
Zampieri, D., & Mamolo, M. G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200819151342 · Cited by 15 · see citing works
New Era of TB Drug Discovery and Its Impact on Disease Management
Zheng, X., & Av‐Gay, Y. (2016) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-016-0098-0 · Cited by 17 · see citing works
Rani, A., Viljoen, A. J., Sumanjit, et al. (2017) · ChemistrySelect · doi:10.1002/slct.201702220 · Cited by 15 · see citing works
Zárate-Bladés, C. R., Rodrigues, R. F., Souza, P., Rios, W. M., Soares, L. S., Rosada, R. S., Brandão, I. T., Masson, A. P., Floriano, E. M., Ramos, S. G., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23417 · Cited by 15 · see citing works
Bedaquiline: A New Hope to Treat Multi-Drug Resistant Tuberculosis
Patel, R. V., Riyaz, S., & Park, S. J. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929114822 · Cited by 14 · see citing works
The Crosstalk Between HIV-TB Co-Infection and Associated Resistance in the Indian Population
Jadhav, S., Nair, A., Mahajan, P., & Nema, V. (2024) · Venereology · doi:10.3390/venereology3040015 · Cited by 14 · see citing works
“Collaborative efforts between healthcare providers, researchers, policymakers, and community stakeholders are indispensable for developing evidence-based interventions and achieving sustainable improvements in public health outcomes.”
McNeil, M. B., Cheung, C., Waller, N. J. E., Adolph, C., Chapman, C. L., Seeto, N. E. J., Jowsey, W. J., Li, Z., Hameed, H. M. A., Zhang, T., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.980844 · Cited by 12 · see citing works
“…et al., 2020; Kamariah et al., 2020; Denny, 2021; Choi et al., 2022; Hards et al., 2022), of which frontiersin.org BDQ is the most clinically advanced and was FDA approved for the treatment of multi-drug resistant M. tuberculosis in 2012 (Diacon et al., 2012; Cohen, 2013; Diacon et al., 2014).”
BackgroundMethodNext-generation antimicrobials: from chemical biology to first-in-class drugs
Ang, M. L. T., Murima, P., & Pethe, K. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0645-0 · Cited by 13 · see citing works
“…and single-channel images, the algorithm precisely segments and identifies the nuclei and cytoplasm of mammalian host cells as well as the intracellular parasites infecting the cells to produce various statistical parameters that can be used to assess both drug responses and compound…”
BackgroundHarris, P. W. R., Cook, G. M., Leung, I. K. H., et al. (2016) · Australian Journal of Chemistry · doi:10.1071/ch16499 · Cited by 13 · see citing works
- Authors
- Cohen, J.
- Venue
- Science
- Published
- 2013-01-11
- Volume
- 339
- Issue
- 6116
- Pages
- 130-130
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1972806716
- Cited by
- 166
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 7 · 2017: 17 · 2016: 18 · 2015: 18 · 2014: 18 · 2013: 24
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Surgery › Infectious Diseases and Tuberculosis
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- tuberculosis, drug approval, FDA approval, tuberculosis treatment, drug development
- MeSH terms
- Antitubercular Agents, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Mycobacterium tuberculosis, Quinolines, United States, United States Food and Drug Administration, Drug Approval, Tuberculosis, Multidrug-Resistant, Drug Resistance, Multiple, Bacterial, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
